STARTAR: Prostate Cancer with a Rising PSA after Prostatectomy - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if adding the study drugs apalutamide and docetaxel chemotherapy to a standard treatment for prostate cancer is more effective than the standard treatment alone.
Prostate cancer with a rising PSA after prostatectomy
Who Can Participate in the Study?
Patients with prostate cancer who have had a prostatectomy and whose PSA has started to rise after surgery.
What is Involved?
If you choose to join this study, you will:
Enter a screening period that includes a physical exam, imaging scans, blood draws, and quality-of-life surveys.
Once you've completed the screening period, you will
- Receive the study drugs apalutamide and docetaxel in addition to standard-of-care androgen deprivation therapy (ADT) and radiation therapy over a period of 36 weeks.
- Return to clinic at least every four weeks for exams, surveys and other procedures
- Once you finish the study treatment, you will have follow-up visits every 3 months for 3 years